Recombinant human interferon-α does not alter reward behavior, or neuroimmune and neuroendocrine activation in rats

Richard De La Garza, Gregory M. Asnis, Erika Pedrosa, Cordelia Stearns, Alexandra L. Migdal, John F. Reinus, Rajendra Paladugu, Sridevi Vemulapalli

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Recombinant human interferon-α (IFN-α) induces depression, and neuroendocrine and neuroimmune activation, in a significant number of patients undergoing treatment for viral illnesses (e.g., hepatitis C), yet these effects have not been consistently reproduced in rodents. As such, we sought to determine the effects of acute or chronic IFN-α treatment on basic reward and immobility in the forced swim test (FST), neuroendocrine and neuroimmune activation, and monoamine turnover in brain. In the first experiment, male Wistar rats (N = 7/group) treated with human recombinant IFN-α (100,000 IU/kg, i.p.), as compared to saline, did not exhibit alterations to rate of sucrose pellet self-administration or total reinforcers obtained, corticosterone release, plasma IL-6 release, IL-1β or IL-6 mRNA expression in hippocampus, or monoamine turnover in prefrontal cortex, striatum, nucleus accumbens, or amygdala. However, acute IFN-α decreased body weight and produced a trend toward reduced food consumption in the home cage 2 h after injection. In the second experiment, Wistar rats (N = 4/group) were subjected to a chronic treatment regimen of saline or IFN-α (100,000 IU/kg, i.p.) once daily for 14 consecutive days. The data reveal that animals exposed to chronic IFN-α exhibited similar amounts of time immobile and similar latencies to primary immobility in the FST as compared to saline-treated controls. Chronic IFN-α did not induce corticosterone release, plasma TNF-α, or IL-6 release. Tissue monoamine analysis revealed that chronic IFN-α reduced DA levels in prefrontal cortex, and decreased 5-HT levels and increased 5-HT turnover in amygdala. In the third experiment, Wistar rats (N = 4/group) were exposed to either acute or chronic pegylated IFN-α (pegIFN-α: 3.25, 10 or 75 mg/kg, i.p.) at one of several time points from 1 h to 23 days. The data reveal that neither acute nor chronic pegIFN-α induced corticosterone release. Overall, the current report demonstrates that neither acute nor chronic IFN-α induced depressive-like behavior and neither IFN-α nor peg-IFN-α was capable of inducing neuroendocrine or neuroimmune activation. Despite the neurochemical alterations observed in the chronic treatment regimen, the data indicate that recombinant human IFN-α does not produce a robust model of depressive-like behavior in rodents.

Original languageEnglish (US)
Pages (from-to)781-792
Number of pages12
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume29
Issue number5
DOIs
StatePublished - Jun 2005

Fingerprint

Reward
Interferons
Corticosterone
Wistar Rats
Interleukin-6
Amygdala
Prefrontal Cortex
Rodentia
Serotonin
Self Administration
Nucleus Accumbens
Therapeutics
Hepatitis C
Interleukin-1
Sucrose
Hippocampus
Body Weight
Depression

Keywords

  • Anhedonia
  • Corticosterone
  • Depression
  • IL-1β
  • IL-6
  • Interferon-α

ASJC Scopus subject areas

  • Biological Psychiatry
  • Pharmacology

Cite this

Recombinant human interferon-α does not alter reward behavior, or neuroimmune and neuroendocrine activation in rats. / De La Garza, Richard; Asnis, Gregory M.; Pedrosa, Erika; Stearns, Cordelia; Migdal, Alexandra L.; Reinus, John F.; Paladugu, Rajendra; Vemulapalli, Sridevi.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 29, No. 5, 06.2005, p. 781-792.

Research output: Contribution to journalArticle

De La Garza, Richard ; Asnis, Gregory M. ; Pedrosa, Erika ; Stearns, Cordelia ; Migdal, Alexandra L. ; Reinus, John F. ; Paladugu, Rajendra ; Vemulapalli, Sridevi. / Recombinant human interferon-α does not alter reward behavior, or neuroimmune and neuroendocrine activation in rats. In: Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2005 ; Vol. 29, No. 5. pp. 781-792.
@article{911ebdc7d8084d30aff09e831613222d,
title = "Recombinant human interferon-α does not alter reward behavior, or neuroimmune and neuroendocrine activation in rats",
abstract = "Recombinant human interferon-α (IFN-α) induces depression, and neuroendocrine and neuroimmune activation, in a significant number of patients undergoing treatment for viral illnesses (e.g., hepatitis C), yet these effects have not been consistently reproduced in rodents. As such, we sought to determine the effects of acute or chronic IFN-α treatment on basic reward and immobility in the forced swim test (FST), neuroendocrine and neuroimmune activation, and monoamine turnover in brain. In the first experiment, male Wistar rats (N = 7/group) treated with human recombinant IFN-α (100,000 IU/kg, i.p.), as compared to saline, did not exhibit alterations to rate of sucrose pellet self-administration or total reinforcers obtained, corticosterone release, plasma IL-6 release, IL-1β or IL-6 mRNA expression in hippocampus, or monoamine turnover in prefrontal cortex, striatum, nucleus accumbens, or amygdala. However, acute IFN-α decreased body weight and produced a trend toward reduced food consumption in the home cage 2 h after injection. In the second experiment, Wistar rats (N = 4/group) were subjected to a chronic treatment regimen of saline or IFN-α (100,000 IU/kg, i.p.) once daily for 14 consecutive days. The data reveal that animals exposed to chronic IFN-α exhibited similar amounts of time immobile and similar latencies to primary immobility in the FST as compared to saline-treated controls. Chronic IFN-α did not induce corticosterone release, plasma TNF-α, or IL-6 release. Tissue monoamine analysis revealed that chronic IFN-α reduced DA levels in prefrontal cortex, and decreased 5-HT levels and increased 5-HT turnover in amygdala. In the third experiment, Wistar rats (N = 4/group) were exposed to either acute or chronic pegylated IFN-α (pegIFN-α: 3.25, 10 or 75 mg/kg, i.p.) at one of several time points from 1 h to 23 days. The data reveal that neither acute nor chronic pegIFN-α induced corticosterone release. Overall, the current report demonstrates that neither acute nor chronic IFN-α induced depressive-like behavior and neither IFN-α nor peg-IFN-α was capable of inducing neuroendocrine or neuroimmune activation. Despite the neurochemical alterations observed in the chronic treatment regimen, the data indicate that recombinant human IFN-α does not produce a robust model of depressive-like behavior in rodents.",
keywords = "Anhedonia, Corticosterone, Depression, IL-1β, IL-6, Interferon-α",
author = "{De La Garza}, Richard and Asnis, {Gregory M.} and Erika Pedrosa and Cordelia Stearns and Migdal, {Alexandra L.} and Reinus, {John F.} and Rajendra Paladugu and Sridevi Vemulapalli",
year = "2005",
month = "6",
doi = "10.1016/j.pnpbp.2005.03.008",
language = "English (US)",
volume = "29",
pages = "781--792",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Recombinant human interferon-α does not alter reward behavior, or neuroimmune and neuroendocrine activation in rats

AU - De La Garza, Richard

AU - Asnis, Gregory M.

AU - Pedrosa, Erika

AU - Stearns, Cordelia

AU - Migdal, Alexandra L.

AU - Reinus, John F.

AU - Paladugu, Rajendra

AU - Vemulapalli, Sridevi

PY - 2005/6

Y1 - 2005/6

N2 - Recombinant human interferon-α (IFN-α) induces depression, and neuroendocrine and neuroimmune activation, in a significant number of patients undergoing treatment for viral illnesses (e.g., hepatitis C), yet these effects have not been consistently reproduced in rodents. As such, we sought to determine the effects of acute or chronic IFN-α treatment on basic reward and immobility in the forced swim test (FST), neuroendocrine and neuroimmune activation, and monoamine turnover in brain. In the first experiment, male Wistar rats (N = 7/group) treated with human recombinant IFN-α (100,000 IU/kg, i.p.), as compared to saline, did not exhibit alterations to rate of sucrose pellet self-administration or total reinforcers obtained, corticosterone release, plasma IL-6 release, IL-1β or IL-6 mRNA expression in hippocampus, or monoamine turnover in prefrontal cortex, striatum, nucleus accumbens, or amygdala. However, acute IFN-α decreased body weight and produced a trend toward reduced food consumption in the home cage 2 h after injection. In the second experiment, Wistar rats (N = 4/group) were subjected to a chronic treatment regimen of saline or IFN-α (100,000 IU/kg, i.p.) once daily for 14 consecutive days. The data reveal that animals exposed to chronic IFN-α exhibited similar amounts of time immobile and similar latencies to primary immobility in the FST as compared to saline-treated controls. Chronic IFN-α did not induce corticosterone release, plasma TNF-α, or IL-6 release. Tissue monoamine analysis revealed that chronic IFN-α reduced DA levels in prefrontal cortex, and decreased 5-HT levels and increased 5-HT turnover in amygdala. In the third experiment, Wistar rats (N = 4/group) were exposed to either acute or chronic pegylated IFN-α (pegIFN-α: 3.25, 10 or 75 mg/kg, i.p.) at one of several time points from 1 h to 23 days. The data reveal that neither acute nor chronic pegIFN-α induced corticosterone release. Overall, the current report demonstrates that neither acute nor chronic IFN-α induced depressive-like behavior and neither IFN-α nor peg-IFN-α was capable of inducing neuroendocrine or neuroimmune activation. Despite the neurochemical alterations observed in the chronic treatment regimen, the data indicate that recombinant human IFN-α does not produce a robust model of depressive-like behavior in rodents.

AB - Recombinant human interferon-α (IFN-α) induces depression, and neuroendocrine and neuroimmune activation, in a significant number of patients undergoing treatment for viral illnesses (e.g., hepatitis C), yet these effects have not been consistently reproduced in rodents. As such, we sought to determine the effects of acute or chronic IFN-α treatment on basic reward and immobility in the forced swim test (FST), neuroendocrine and neuroimmune activation, and monoamine turnover in brain. In the first experiment, male Wistar rats (N = 7/group) treated with human recombinant IFN-α (100,000 IU/kg, i.p.), as compared to saline, did not exhibit alterations to rate of sucrose pellet self-administration or total reinforcers obtained, corticosterone release, plasma IL-6 release, IL-1β or IL-6 mRNA expression in hippocampus, or monoamine turnover in prefrontal cortex, striatum, nucleus accumbens, or amygdala. However, acute IFN-α decreased body weight and produced a trend toward reduced food consumption in the home cage 2 h after injection. In the second experiment, Wistar rats (N = 4/group) were subjected to a chronic treatment regimen of saline or IFN-α (100,000 IU/kg, i.p.) once daily for 14 consecutive days. The data reveal that animals exposed to chronic IFN-α exhibited similar amounts of time immobile and similar latencies to primary immobility in the FST as compared to saline-treated controls. Chronic IFN-α did not induce corticosterone release, plasma TNF-α, or IL-6 release. Tissue monoamine analysis revealed that chronic IFN-α reduced DA levels in prefrontal cortex, and decreased 5-HT levels and increased 5-HT turnover in amygdala. In the third experiment, Wistar rats (N = 4/group) were exposed to either acute or chronic pegylated IFN-α (pegIFN-α: 3.25, 10 or 75 mg/kg, i.p.) at one of several time points from 1 h to 23 days. The data reveal that neither acute nor chronic pegIFN-α induced corticosterone release. Overall, the current report demonstrates that neither acute nor chronic IFN-α induced depressive-like behavior and neither IFN-α nor peg-IFN-α was capable of inducing neuroendocrine or neuroimmune activation. Despite the neurochemical alterations observed in the chronic treatment regimen, the data indicate that recombinant human IFN-α does not produce a robust model of depressive-like behavior in rodents.

KW - Anhedonia

KW - Corticosterone

KW - Depression

KW - IL-1β

KW - IL-6

KW - Interferon-α

UR - http://www.scopus.com/inward/record.url?scp=21244476086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21244476086&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2005.03.008

DO - 10.1016/j.pnpbp.2005.03.008

M3 - Article

VL - 29

SP - 781

EP - 792

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 5

ER -